Product
Supplier
Encyclopedia
Inquiry
Home > News > Market Flash > The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus

The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus

ECHEMI 2025-09-24

Eli Lilly’s once-daily oral GLP-1, orforglipron, outperformed Novo Nordisk’s oral semaglutide (Rybelsus) in a head-to-head diabetes study, reinforcing Lilly’s bid to lead in pills as well as injectables; the result extends the company’s incretin edge beyond Mounjaro/Zepbound and signals fiercer competition for oral market share as capacity and adherence dynamics shift toward convenient formulations. 

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.